Nivolumab is a humanized monoclonal antibody targeting PD-1, utilized for its anti-tumor activity in research on melanoma, non-small cell lung cancer, and renal cell carcinoma. It is widely applied in both in vitro assays and in vivo models to investigate immune checkpoint blockade mechanisms and therapeutic efficacy.
Konzentration:
10.2 mg/mL
Molekulargewicht:
146 kDa
Reinheit:
98.00% (May vary between batches)
CAS Nummer:
[946414-94-4]
Target-Kategorie:
PD-1/PD-L1
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten